Black and Latino people use 10% to 40% fewer prescription drugs because of high costs, according to a report by Patients for Affordable Drugs.
3 months ago

This statistic reveals the revenues generated by top product Revlimid from 2008 to 2023. In 2023, one of the leading cancer drugs globally generated revenues...
11 months ago

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established drugs like blood thinner Eliquis...
2 months ago

Dr Reddy's share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to 'Buy' with a target of ₹1553, highlighting proactive...
1 week ago

Dr Reddy's Laboratories and other pharma companies are battling an antitrust lawsuit in the US over the $8 billion blockbuster cancer drug Revlimid generic.
9 months ago

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
2 months ago

While Dr Reddy's recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug...
11 months ago

A major factor driving higher drug costs is the patent system, which grants pharmaceutical manufacturers a 20-year exclusive right to “make, use, sell, and...
7 months ago

Years after Martin Shkreli kicked off a drug pricing controversy around the HIV drug Daraprim, the price of the drug has not fallen to pre-Shkreli figures...
7 months ago

Dr Reddy's Laboratories Inc have been named defendants in an anti-trust complaint pertaining to cancer drug Revlimid (Lenalidomide).
10 months ago